https://www.selleckchem.com/
7% decrease in NPS scores from 89.3 at baseline to 52.1 at 12 months posttreatment (P .05). In addition, there was a 33.3% decrease in MHDs per month from 19.8 at baseline to 13.2 at 12 months posttreatment (P .05). Administration of anti-CGRP medications significantly improved neuropathic pain in patients who also had chronic migraine. To confirm these promising outcomes, it would be worthwhile to conduct a blinded, randomized study with a larger population of patients. Administration of anti-CGRP medications significantly improved neuropathic pa
Like
Comment
Share
